Invasive Aspergillosis (IA) is a devastating and frequently fatal infection in immunocompromised patients, in part because of poor early detection tools. The ability to promptly launch antifungal therapy for Aspergillosis and other invasive fungal diseases is critical for positive patient outcomes. However, early detection is complicated by low levels of antigenic markers that signal disease onset and by poor specificity of current diagnostic assays.
The aim of this proposal is to develop an antibody-based diagnostics platform comprised of new monoclonal antibodies coupled with the ultrasensitive detection capabilities of surface enhanced Raman spectroscopy and gold nanoparticle sandwich assays. To address the challenges in the early detection of IA, we have assembled a collaborative research team of scientists from the University of Utah and North Dakota State University composed of immunologists with expertise in monoclonal antibody development and screening for Aspergillus spp;medical microbiologists with strengths in basic mycology, fungal assay development and validation;analytical chemists with a strong focus in the creation of novel, ultrasensitive and selective diagnostic tests;and infectious disease clinicians with proficiency in the design and implementation of patient-oriented research. We will address the specific aims of this project in two phases.
The aims for the R21 phase of the project are: (1) Identify protein-based fungal targets through the development of monoclonal antibodies from unique, stage-specific biomarkers of Aspergillus spp. (2) Evaluate monoclonal antibody combinations with surface enhanced Raman spectroscopy-based sandwich immunoassay techniques. (3) Define assay performance metric comparisons using diverse human sample matrices. Upon meeting the milestones of the first stage of the project, the aims of the R33 phase are: (1) Characterize fungal target proteins based on growth stage specificity. (2) Optimize analysis protocols to maximize fungal detection. (3) Standardize components of a unique analysis kit for early clinical Aspergillosis diagnosis. The detection strategy created through the successful completion of this project will redefine the diagnosis of IA through augmented sensitivity and specificity, permitting treatment at the earliest stages of disease.

Public Health Relevance

Invasive aspergillosis (IA) is a devastating, frequently fatal infection in immunocompromised and immu- nosupressed patients. Unfortunately, the ability to promptly launch antifungal therapy for IA and other in- vasive fungal diseases is compromised by the poor clinically sensitivity, clinical specificity, and prognos- tic value of existing diagnostic tools. Until IA can be reliably identified at early stages, the morbid- ity/mortality attendant with this dreadful disease will remain unacceptably high. The overall goal of this project is to develop a simple, rapid, and inexpensive laboratory test that will serve as a cornerstone for the confident early diagnosis of IA.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI085476-01
Application #
7780113
Study Section
Special Emphasis Panel (ZAI1-FDS-M (S1))
Program Officer
Ritchie, Alec
Project Start
2010-06-01
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
1
Fiscal Year
2010
Total Cost
$197,492
Indirect Cost
Name
University of Utah
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112